Less than a month after admitting failure in a highly anticipated trial of its only program, Bellerophon Therapeutics is waving the white flag.
US-based biotechnology firm Bellerophon Therapeutics has reported that its Phase III REBUILD clinical trial of INOpulse for the treatment of fibrotic interstitial lung disease (fILD) failed to meet its primary endpoint.
Trial did not meet its primary endpoint related to the change in moderate to vigorous physical activity INOpulse® was safe and well-tolerated, consistent with the overall safety profile demonstrated...
In the five years since Bellerophon Therapeutics’ only program, a device for administering inhaled nitric oxide called INOpulse, flunked its first Phase III study, the New Jersey biotech has kept at it, starting multiple new trials in different indications.
Last Patient Completed Blinded Treatment in REBUILD Phase 3 Trial for INOpulse®; Pivotal Top-line Data Expected in Mid-2023 WARREN, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics,...
WARREN, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing...
Bellerophon Provides Clinical Program Update and Reports Full-Year 2022 Financial Results
Bellerophon Therapeutics Announces $5 Million Registered Direct Offering
Bellerophon Therapeutics Receives IND Clearance from China NMPA to Conduct Phase 3 Clinical Trial in China for INOpulse® in Fibrotic Interstitial Lung Disease
Bellerophon Therapeutics has completed participants enrolment in the Phase III REBUILD study of its pulsatile nitric oxide delivery system, INOpulse, to treat fibrotic interstitial lung disease (fILD).